Joshua Zeidner, MD (IMAGE)

UNC Lineberger Comprehensive Cancer Center

Joshua Zeidner, MD

Caption

“Immunotherapy has led to a paradigm shift in treating cancer, but acute myeloid leukemia has lagged behind other cancers despite extensive data that it may be effective," Zeidner said. "Our study is the first clinical trial to investigate the role of pembrolizumab in combination with intensive chemotherapy in patients with acute myeloid leukemia that relapses or is resistant to therapy.”

Credit

UNC Lineberger Comprehensive Cancer Center

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.